1. Generics Bulletin
  2. >>Products
  3. >>Generics

Data Integrity: US FDA Guidance Seeks To Head Off Bioavailability/Bioequivalence Study Problems

 
• By Sue Sutter

Ultimate responsibility for data integrity rests with applicant, even if study is contracted out; testing site management should build a culture of quality, says the guidance, which aims to address the high-profile data integrity problems that have plagued the generic drug industry.

Drawing bullseye
A new guidance takes aim at the data integrity problems that have plagued industry in recent years • Source: Shutterstock

A new US Food and Drug Administration guidance takes aim at heading off a high-profile problem that has troubled the generic drug industry in recent years – fraud and other data integrity issues with bioavailability and bioequivalence studies.

Recommendations in the draft guidance, “Data Integrity for In Vivo Bioavailability and Bioequivalence Studies,” are aimed at addressing the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

Sandoz Warns Of ‘Trade Distortion’ As US Tariffs Hit Penicillins Supply From China

 
• By Dave Wallace

Sandoz’s CEO used the firm’s latest results call to highlight “trade distortion” in the pencillins market as a result of US tariffs, urging European authorities to take action to reduce the region’s “geopolitical exposure” and safeguard the long-term sustainability of European-produced penicillins.

Outgoing Cipla CEO On Key Wins, Unfinished Agenda, Biosimilars ‘Explosion’ To Come

 
• By Anju Ghangurde

Cipla’s global CEO and MD Umang Vohra is moving on handing over the baton to global COO, Achin Gupta. Vohra talks about his innings, where he sees Cipla in 2030 and the impact of the latest FDA action that aims to make biosimilar development faster and less costly.

Biogen Fights To Defend MS Franchise Amid Generic Erosion And Biosimilar Threats

 
• By Dean Rudge

On its third-quarter earnings call, Biogen’s management said the company remains well positioned despite accelerating generic pressure in Europe and the imminent US launch of Sandoz’s Tyruko biosimilar.

Dr Reddy’s Knocked Back On Canadian Semaglutide

 
• By Anju Ghangurde

Dr Reddy's had not ruled out "queries" from the Canadian regulator for generic semaglutide, though it is confident of selling “all its capacity” for the GLP-1 across target markets. A backup CMO site in the US for abatacept is expected to mitigate risks amid tariff and other uncertainties.

More from Products

‘A True Biosimilar’: Amgen Links Amjevita’s Success To Quality And Regulatory Stability

 
• By Dean Rudge

Amgen’s CEO Robert Bradway has reaffirmed confidence in the company’s Humira biosimilar, Amjevita, as the company tackles with an ever-growing population of denosumab biosimilars.

‘Right Thing To Do’: Teva Feels Validated By Partner-Driven Biosimilar Approach

 
• By Dean Rudge

The FDA’s proposal to streamline clinical trials is seen as vindication for Teva’s partnership-driven biosimilar play, as the firm targets $400m in added sales by 2027.

Outgoing Cipla CEO On Key Wins, Unfinished Agenda, Biosimilars ‘Explosion’ To Come

 
• By Anju Ghangurde

Cipla’s global CEO and MD Umang Vohra is moving on handing over the baton to global COO, Achin Gupta. Vohra talks about his innings, where he sees Cipla in 2030 and the impact of the latest FDA action that aims to make biosimilar development faster and less costly.